Upregulation of SPINK2 in acute myeloid leukemia

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (SPINK2) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.

Keywords

• acute myeloid leukemia
• aml
• husi-ii
• serin protease inhibitors
• spink2